Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?

ABSTRACT:

Purpose

In this study, we aimed to evaluate the potential of routine blood markers, serum tumour markers and their combination in predicting RECIST-defined progression in patients with stage IV non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors.

Methods

We employed time-varying statistical models and machine learning classifiers in a Monte Carlo cross-validation approach to investigate the association between RECIST-defined progression and blood markers, serum tumour markers and their combination, in a retrospective cohort of 164 patients with NSCLC.

Results

The performance of the routine blood markers in the prediction of progression free survival was moderate. Serum tumour markers and their combination with routine blood marker

SUBMITTER: Yeghaian M 

PROVIDER: S-EPMC11208229 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature